Abstract
Ductal carcinoma in situ (DCIS), a precursor to invasive breast cancer (IBC), represents 25% of all breast neoplasms. Most are harmless, but some progress to IBC. Yet, almost all DCIS are treated. Learning how to distinguish harmless from hazardous DCIS will save many women with harmless DCIS the burden of overtreatment.